A Study Evaluating the Efficacy of Xanomeline/Trospium (XT) on Cognitive Impairment After 24 and 52 Weeks of Treatment in Adult Participants With Schizophrenia
Clinical trial NCT07084831 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07084831
- Sponsor
- European Group for Research In Schizophrenia
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2027-01-01
- Primary completion
- 2029-01-01
- Enrollment
- 171
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.